PrymaLab AnalyticalSafety data sheet · capsulesPrymaLab LLC · 3705 Music Branch Rd, Ashland, KY 41102
Document number
PL-SDS-142
Revision
1.0 · Oct 3, 2026
S-23 Capsules · 1 catalogue item
For laboratory research use only. Not for human or veterinary use; not a drug, food, dietary supplement, cosmetic or household product.
1Identification
| Product identifier | S-23 — capsules |
|---|---|
| Catalogue items covered | S-23 10mg Capsules PL-S23-10MG-CAP |
| Synonyms / chemical names | S-23: S-23, selective androgen receptor modulator (CAS 1010396-29-8) |
| Recommended use | Laboratory research chemical for in-vitro and animal-model studies by trained personnel. |
| Restrictions on use | Not for human or veterinary use, diagnosis or therapy. Not for use as a drug, food, dietary supplement, cosmetic or in household products. Not for resale to the public for personal use. |
| Supplier | PrymaLab LLC (PrymaLab Analytical), 3705 Music Branch Rd, Ashland, KY 41102, United States · Tel. +1 (606) 465-9063 · michael@prymalab.net · https://prymalab.net |
| Emergency telephone | Poison Help (US, 24 h): 1-800-222-1222 · Supplier (business hours, US Eastern): +1 (606) 465-9063 |
2Hazard(s) identification
Classification of the mixture
- Reproductive toxicity, Category 2 — H361
Label elements
GHS08 — Health hazard
Signal word: Warning
Hazard statements
H361Suspected of damaging fertility or the unborn child.
Precautionary statements
Prevention
P201Obtain special instructions before use.P202Do not handle until all safety precautions have been read and understood.P280Wear protective gloves, protective clothing and eye protection.
Response
P308+P313IF exposed or concerned: Get medical advice/attention.
Storage
P405Store locked up.
Disposal
P501Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.
Hazards not otherwise classified / other hazards
- Pharmacologically active material. Accidental injection, ingestion or absorption may produce systemic effects consistent with the compound's mechanism of action; see Section 11.
- The active ingredient(s) (< 10% of the mixture) have no acute toxicity data.
- Finely divided organic powder may form combustible dust concentrations in air if dispersed in bulk (not expected at laboratory scale).
3Composition / information on ingredients
Hard gelatin capsules containing the active substance blended with microcrystalline cellulose, packed in a sealed bottle.
| Ingredient | CAS No. | Formula | Concentration | Quantity | Ingredient classification |
|---|---|---|---|---|---|
| S-23 S-23, selective androgen receptor modulator | 1010396-29-8 | C18H13ClF4N2O3 | 2.5% w/w of capsule contents (nominal) | 10 mg per capsule | Acute tox. oral 4 · H302 Aquatic chronic 4 · H413 Repr. 2 · H361 |
| Microcrystalline cellulose Microcrystalline cellulose (capsule filler) | 9004-34-6 | (C6H10O5)n | balance of capsule contents | — | not classified |
| Gelatin Gelatin (capsule shell) | 9000-70-8 | — | capsule shell | — | not classified |
Peptides are supplied as the acetate or trifluoroacetate salt unless stated otherwise; the counter-ion and residual water make up the balance of a lyophilized product. Concentration limits used for mixture classification follow OSHA HCS 2012 Appendix A. Concentrations of the active in the capsule contents are calculated for a nominal fill weight of 400 mg; the classification of the pure active substance is given in Section 11 for the case where capsule contents are handled as a powder.
4First-aid measures
| General | If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure. |
|---|---|
| Inhalation | Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor. |
| Skin contact | Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice. |
| Eye contact | Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice. |
| Ingestion | Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell. |
| Most important symptoms and effects | No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption. |
| Indication of immediate medical attention | Treat symptomatically. Show this safety data sheet to the attending physician. No specific antidote is known; monitor for the effects described in Section 11. |
5Fire-fighting measures
| Suitable extinguishing media | Water spray, carbon dioxide, dry chemical or alcohol-resistant foam. Use measures appropriate to the surrounding fire. |
|---|---|
| Unsuitable extinguishing media | None known. Do not use a high-pressure water jet on powders (dust dispersion). |
| Specific hazards | Combustible organic solid; capsule contents may form combustible dust if dispersed in bulk. Thermal decomposition may release carbon monoxide, carbon dioxide and nitrogen oxides. |
| Protective equipment for fire-fighters | Self-contained breathing apparatus and full protective clothing. Prevent run-off from entering drains. |
6Accidental release measures
| Personal precautions | Wear the protective equipment in Section 8. Keep unprotected people away. Avoid dust formation and inhalation of dust. |
|---|---|
| Environmental precautions | Do not allow material to reach drains, surface water or soil. Quantities supplied are small; collect for disposal. |
| Methods for cleaning up | Collect intact capsules. Dampen any spilled powder with water, wipe up with absorbent material and place in a sealed container for disposal. Decontaminate surfaces with 70% alcohol or detergent and water. |
7Handling and storage
| Precautions for safe handling | Do not open or crush capsules unless required for an experiment; if capsule contents are handled as a powder, avoid generating dust and weigh inside a ventilated enclosure. Wash hands after handling. Do not eat, drink or smoke in the handling area. Follow the precautionary statements in Section 2. |
|---|---|
| Conditions for safe storage | Store at room temperature (15–25 °C) in the tightly closed original container, dry and protected from light. Keep the container tightly closed and labelled, out of reach of unauthorised persons (store locked up). |
| Storage temperature | 15–25 °C, dry, protected from light |
| Incompatible materials | Strong oxidising agents, strong acids and bases. |
8Exposure controls / personal protection
| Occupational exposure limits | Microcrystalline cellulose: OSHA PEL 15 mg/m³ (total dust), 5 mg/m³ (respirable fraction); ACGIH TLV 10 mg/m³ (as cellulose). No occupational exposure limits have been established for the active ingredient(s). |
|---|---|
| Engineering controls | Good general laboratory ventilation. Weigh or manipulate dry powder in a ventilated enclosure (powder hood, biosafety cabinet or fume hood). An eyewash station should be available. |
| Eye / face protection | Safety glasses with side shields (ANSI Z87.1 / EN 166). |
| Skin protection | Nitrile gloves (inspect before use; change after contamination) and a laboratory coat. |
| Respiratory protection | Not normally required with the engineering controls above. Where dust cannot be controlled, use a NIOSH-approved N95 (or P2) particulate respirator. |
| Hygiene measures | Wash hands after handling and before breaks. Remove contaminated clothing. Do not pipette by mouth. |
9Physical and chemical properties
| Physical state / appearance | Solid. Hard gelatin capsules containing a white to off-white powder. |
|---|---|
| Odour / odour threshold | Characteristic (Cayman) |
| pH | Not applicable (solid) |
| Melting / freezing point | Undetermined (Cayman); not documented (ChemicalBook) |
| Boiling point | Undetermined |
| Flash point / flammability | Not applicable (non-flammable solid); combustible organic material |
| Vapour pressure / density | Negligible (solid) |
| Relative density | No data available (bulk density of lyophilized cake is low) |
| Solubility | Cayman: DMF 20 mg/ml; DMSO 14 mg/ml; ethanol 10 mg/ml; DMF:PBS (1:4) 0.2 mg/ml. ChemicalBook: slightly soluble in chloroform and methanol. Practically insoluble in water |
| Partition coefficient (log Pow) | No data available (lipophilic aryl-propionamide) |
| Auto-ignition / decomposition temperature | No data available; peptides decompose above about 200 °C |
| Molecular formula / mass | S-23: C18H13ClF4N2O3, 416.8 g/mol |
| Other information | Not flammable. CAS 1010396-29-8; C18H13ClF4N2O3, MW 416.8; halogenated (Cl, F) non-steroidal SARM |
10Stability and reactivity
| Reactivity | No hazardous reactivity under normal laboratory conditions. |
|---|---|
| Chemical stability | Stable when stored as recommended (Section 7). Lyophilized peptides are hygroscopic and degrade faster once moist or reconstituted. |
| Possibility of hazardous reactions | None known. |
| Conditions to avoid | Heat, direct light, moisture, repeated freeze–thaw cycles. |
| Incompatible materials | Strong oxidising agents, strong acids and bases. |
| Hazardous decomposition products | Carbon oxides and nitrogen oxides, hydrogen halides on combustion. No hazardous decomposition under recommended storage. |
11Toxicological information
Likely routes of exposure: Ingestion; inhalation of dust and skin/eye contact if capsules are opened.
Symptoms related to the physical, chemical and toxicological characteristics: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.
S-23 S-23, selective androgen receptor modulator · CAS 1010396-29-8
Substance classification adopted: Acute tox. oral 4 · H302 Aquatic chronic 4 · H413 Repr. 2 · H361
Cayman Chemical and ChemicalBook SDSs (H302, H413); Reproductive toxicity Category 2 self-classified (SARM developed as a male contraceptive; suppresses spermatogenesis).
| Acute toxicity, oral | No LD50 in either SDS; classified Acute Tox. 4 oral (H302) by Cayman - estimate based, no value quoted |
|---|---|
| Acute toxicity, dermal | No data available |
| Acute toxicity, inhalation | No data available |
| Skin corrosion/irritation | No irritant effect (Cayman); no data (ChemicalBook) |
| Serious eye damage/irritation | No irritating effect (Cayman) |
| Respiratory or skin sensitisation | No sensitizing effects known (Cayman) |
| Germ cell mutagenicity | No data available |
| Carcinogenicity | Not listed by IARC, NTP or OSHA-Ca |
| Reproductive toxicity | No data available in SDSs; however S-23 is a potent androgen-receptor agonist studied as a reversible male contraceptive because it suppresses spermatogenesis and gonadotropins in rats - a clear reproductive-toxicity concern (see notes) |
| STOT, single exposure | No data available |
| STOT, repeated exposure | No data available |
| Aspiration hazard | No data available |
- Selective androgen receptor modulator (SARM). No supplier SDS assigns a reproductive classification, but SARMs act on the androgen receptor, suppress gonadotropins and spermatogenesis in animal and human studies and are prohibited at all times under WADA class S1.2. PrymaLab therefore self-classifies the substance as Reproductive toxicity Category 2 (H361) by expert judgement.
Mixture classification: the ingredient classifications above were combined using the additivity and cut-off rules of OSHA HCS 2012 Appendix A (acute toxicity estimate calculation; 10% cut-off for skin and eye irritation; 0.1% for carcinogenicity, reproductive toxicity and respiratory sensitisation; 1.0% for skin sensitisation and STOT; 20% for respiratory tract irritation).
Carcinogen listings: no ingredient is listed as a carcinogen by IARC, NTP or OSHA.
12Ecological information
S-23: Cayman classifies Aquatic Chronic 4 (H413, may cause long lasting harmful effects to aquatic life) though it gives no measured aquatic toxicity, persistence or bioaccumulation data; halogenated lipophilic compound - avoid release to the environment.
Persistence and degradability: peptides and amino acids are expected to biodegrade readily; benzyl alcohol is readily biodegradable (92–96% in 14 days, OECD 301C). Bioaccumulative potential: low (hydrophilic, log Pow < 3 where known). Mobility in soil: water-soluble; mobile. PBT/vPvB: not expected to meet the criteria. Other adverse effects: none known. Do not release concentrated material to the environment.
13Disposal considerations
Dispose of unused material and contaminated packaging through a licensed chemical-waste contractor in accordance with federal (40 CFR 261), state and local regulations; the material is not a listed RCRA hazardous waste but is classified as hazardous for supply and should be managed as chemical waste. Do not pour down the drain. Small residues may be inactivated with 10% bleach for 30 minutes before disposal where local rules allow. Empty glass vials and cartridges: remove labels or deface them before recycling or disposal.
14Transport information
| DOT (49 CFR) / IATA / IMDG | Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used. |
|---|---|
| UN number / proper shipping name / class / packing group | Not applicable. |
15Regulatory information
| OSHA Hazard Communication Standard (29 CFR 1910.1200) | Hazardous: Reproductive toxicity (Category 2). |
|---|---|
| TSCA (Toxic Substances Control Act) | S-23: not listed on the TSCA Inventory (supplied for research and development; 40 CFR 720.36); Microcrystalline cellulose: listed on the TSCA Inventory; Gelatin: listed on the TSCA Inventory. |
| SARA Title III (Sections 302, 311/312, 313), CERCLA | No ingredient is listed as an extremely hazardous substance (Section 302), a Section 313 toxic chemical or a CERCLA hazardous substance. Section 311/312 hazard categories follow the classification in Section 2. |
| California Proposition 65 | No ingredient is listed as known to the State of California to cause cancer or reproductive toxicity. |
| State right-to-know lists | No ingredient is listed. |
| US FDA | Research chemical. Not an FDA-approved drug product; not evaluated for safety or efficacy in humans or animals; not GRAS; not a dietary ingredient. Sold for laboratory research use only. |
| US DEA controlled substances | No ingredient is scheduled under the Controlled Substances Act at the revision date. |
| Anti-doping (information only) | S-23: WADA class S1. |
| International | The classification in Section 2 applies equally under EU CLP (Regulation (EC) 1272/2008) and other UN GHS implementations; peptides of this kind are generally not registered under REACH (research and development use). |
16Other information
| Revision | Revision 1.0, October 3, 2026 — first issue. Prepared by PrymaLab Analytical, PrymaLab LLC. |
|---|---|
| Classification method | Calculated from the ingredient classifications (Section 3) with the OSHA HCS 2012 Appendix A mixture rules; ingredient classifications were adopted from the supplier safety data sheets listed below with the PrymaLab policy adjustments stated in Section 11. Policy: Cayman Chemical is the primary reference for research peptides and novel small molecules and Sigma-Aldrich/Merck for commodity chemicals; a more conservative manufacturer or ECHA classification is adopted where internally consistent; SARMs, GLP-1 receptor agonists, GnRH analogues and gonadotropins carry reproductive-toxicity classifications by expert judgement. Concentrations of the active in the capsule contents are calculated for a nominal fill weight of 400 mg; the classification of the pure active substance is given in Section 11 for the case where capsule contents are handled as a powder. |
| Sources consulted | Cayman Chemical; ChemicalBook; Spectrum Chemical; Sigachi Industries; Parchem; Fisher Scientific / Acros Organics; Electron Microscopy Sciences. |
| Abbreviations | ATE acute toxicity estimate · CAS Chemical Abstracts Service · GHS Globally Harmonized System · HCS Hazard Communication Standard · IARC International Agency for Research on Cancer · LD50/LC50 median lethal dose/concentration · NTP National Toxicology Program · OEL occupational exposure limit · PEL permissible exposure limit · STOT specific target organ toxicity · TLV threshold limit value · WADA World Anti-Doping Agency. |
